Effects of SLC31A1 and ATP7B polymorphisms on platinum resistance in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiotherapy
Effects of SLC31A1 and ATP7B polymorphisms on platinum resistance in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiotherapy
复制标题
DOI：
10.1007/s12032-020-01450-1
复制
发表时间：
2021-01-07
期刊：
影响因子：
3.4
通讯作者：
Miura, Masatomo
中科院分区：
文献类型：
--
作者：
Fujita, Kazuma;Motoyama, Satoru;Miura, Masatomo
研究了SLC 31 A1（蛋白质：铜转运蛋白1）rs 10981694 A > C和ATP 7 B（蛋白质：P型三磷酸腺苷酶7 B）rs 9535828 A > G多态性与104例接受新辅助放化疗（CRT）的日本食管鳞状细胞癌（ESCC）患者总生存期和无病生存期的关系。化疗包括第1-5天延长输注5-氟尿嘧啶（800 mg/m2/天），第1天输注顺铂或奈达铂（80 mg/m2/天）。中位（范围）随访时间为47（6-127）个月。5年总生存率和无病生存率分别为71.2%和60.6%。SLC 31 A1 rs 10981694 C等位基因患者的5年总生存率显著高于rs 10981694 A/A基因型患者（91.7% vs. 65.0%，P = 0.018）。SLC 31 A1 rs 10981694 C等位基因患者的5年无病生存率显著高于rs 10981694 A/A基因型患者（79.2% vs. 55.0%，P = 0.043）。此外，单变量和多变量分析显示，SLC 31 A1 rs 10981694 A > C多态性是影响新辅助CRT后5年总生存率的重要预后因素。然而，手术后的总体和无病生存率在ATP 7 B rs 9535828基因型之间没有显著差异。总之，只有SLC 31 A1 rs 10981694 A/A基因型是5年总生存率较差的独立预测因子。因此，在ESCC患者的新辅助CRT中，铂的效果受到SLC 31 A1 rs 10981694 A > C多态性的影响。在设计新辅助CRT方案或ESCC治疗策略时，应考虑该多态性的存在。
The relationship between the SLC31A1 (protein: copper transporter 1) rs10981694 A > C and ATP7B (protein: P-type adenosine triphosphatase 7B) rs9535828 A > G polymorphisms on the overall survival and disease-free survival of 104 Japanese patients with esophageal squamous cell carcinoma (ESCC) receiving neoadjuvant chemoradiotherapy (CRT) was investigated. Chemotherapy consisted of protracted infusion of 5-fluoracil (800 mg/m(2)/day) on days 1-5 and cisplatin or nedaplatin (80 mg/m(2)/day) on day 1. The median (range) follow-up was 47 (6-127) months. The 5-year overall and disease-free survival rates were 71.2% and 60.6%, respectively. The 5-year overall survival rate was significantly higher in patients with the SLC31A1 rs10981694 C allele compared with the rs10981694 A/A genotype (91.7% vs. 65.0%, P = 0.018). The 5-year disease-free survival rate was significantly higher in patients with the SLC31A1 rs10981694 C allele compared with the rs10981694 A/A genotype (79.2% vs. 55.0%, P = 0.043). In addition, univariate and multivariate analyses showed the SLC31A1 rs10981694 A > C polymorphism to be a significant prognostic factor affecting 5-year overall survival after neoadjuvant CRT. However, the overall and disease-free survival rates after surgery did not differ significantly among the ATP7B rs9535828 genotypes. In conclusion, only the SLC31A1 rs10981694 A/A genotype was an independent predictor of a poorer 5-year overall survival. Therefore, in neoadjuvant CRT for ESCC patients, the effect of platinum was affected by the SLC31A1 rs10981694 A > C polymorphism. The presence of this polymorphism should be considered when devising neoadjuvant CRT regimens or treatment strategies for ESCC.